目的:探讨复方丹参注射液联合拉贝洛尔对子痫患者肝功能与胎盘生长因子的影响。方法:选取70例子痫患者,随机分为对照组和观察组各35例。对照组采用拉贝洛尔进行治疗,观察组在对照组的治疗基础上联合复方丹参注射液治疗,联合分析两组肝功...目的:探讨复方丹参注射液联合拉贝洛尔对子痫患者肝功能与胎盘生长因子的影响。方法:选取70例子痫患者,随机分为对照组和观察组各35例。对照组采用拉贝洛尔进行治疗,观察组在对照组的治疗基础上联合复方丹参注射液治疗,联合分析两组肝功能[丙氨酸转氨酶(ALT)、谷草转氨酶(AST)、总蛋白(TP)、白蛋白(ALB)]、血液流变学指标、胎盘生长因子(PLGF)、血清胰岛素样生长因子-1(IGF-1)及临床指标情况。结果:治疗后,观察组患者丙氨酸转氨酶(ALT)、谷草转氨酶(AST)水平显著低于对照组,观察组总蛋白(TP)、白蛋白(ALB)水平显著高于对照组,差异有统计学意义(P<0.05);观察组治疗后高切及低切全血黏度,血浆黏度及红细胞刚性指数评估指标明显低于对照组,差异有统计学意义(P<0.05);观察组治疗后PLGF及IGF-1评估指标水平高于对照组,差异有统计学意义(P<0.05);观察组治疗后生产孕周、新生儿体重指标、胎盘重量及新生儿1 min Apgar评分情况高于对照组,差异有统计学意义(P<0.05)。结论:对子痫患者采用复方丹参注射液联合拉贝洛尔治疗,可有效控制患者的病情,改善患者的肝功能及胎盘生长因子状况,且安全性较高。展开更多
Objective: The purpose of this study was to determine if maternal serum concentrations of placenta growth factor(PlGF) and soluble Fms-like tyrosine kinase 1 receptor(s-Flt1) are more abnormal in patients with severe ...Objective: The purpose of this study was to determine if maternal serum concentrations of placenta growth factor(PlGF) and soluble Fms-like tyrosine kinase 1 receptor(s-Flt1) are more abnormal in patients with severe preeclampsia compared with mild preeclampsia. Study design: Serum samples were collected from 32 control patients and 80 patients with mild or severe preeclampsia. PlGF and s-Flt1 concentrations were quantitated by enzyme-linked immunosorbent assay (ELISA). Results are expressed as median(Q1-Q3) unless stated otherwise. After normalization, serum markers were compared using one-way analysis of covariance (ANCOVA). Results: Patients with preeclampsia had decreased levels of PlGF(75.1±14 vs 391±54 pg/mL, P< .0001) and elevated s-Flt1 concentration(1081±108 vs 100.1±26.9 pg/mL, P< .0001) compared with the respective controls(mean±SEM). PlGF concentration was lower in patients with mild preeclampsia compared with severe, respectively(67 pg/mL [39-158] vs 24 pg/mL [4-57], P< .02). s-Flt1 was not different between mild and severe preeclampsia(674 pg/mL [211-1297] vs 1015 pg/mL [731-1948], P=.08). Conclusion: PlGF and s-Flt1 serum levels are abnormal in patients with preeclampsia compared with controls, but only PlGF is more abnormal in severe preeclampsia compared with mild preeclampsia.展开更多
Objective: To assess the possible role of human Urotensin-II (hU-II), a vaso active peptide, in the pathophysiology of preeclampsia-eclampsia prospectively. Study design: Sixty subjects, 30 with a diagnosis of preecla...Objective: To assess the possible role of human Urotensin-II (hU-II), a vaso active peptide, in the pathophysiology of preeclampsia-eclampsia prospectively. Study design: Sixty subjects, 30 with a diagnosis of preeclampsia-eclampsia (g roup I) and 30 control subjects (group II), who had been admitted between Januar y, 2002 and December, 2002, were taken into the study. Patients in group I had a n increase in blood pressure after 28th week of gestation, without any history o f hypertensive disease and/or preeclampsia or eclampsia. hU-II levels were asse ssed using a radioimmunoassay method. Results: No statistically significant diff erence in terms of age, gestational age, gravidity, abortion and parity was dete cted among groups (P >0.05). Plasma hU-II levels in the preeclampsia-eclampsia and control groups were 10.11 ±5.94 pg/mL and 3.93 ±1.73 pg/mL, respectively. Difference between plasma hU-II levels of the two groups was found to be stati stically significant (P < .00001). Also there was correlation between hU-II lev els and mean arterial pressures in both groups (r = 0.73, P < 0.0001 and r = 0.7 2, P < 0.0001 for groups I and II, respectively). Conclusion: Results of our stu dy strongly suggest an important role for hU-II in the pathophysiology of preec lampsia-eclampsia. Further studies concerning placenta and cord blood samples w ill more clearly elucidate the role of Urotensin-II in the pathogenesis of pree clampsia-eclampsia, and its feto-maternal effects.展开更多
文摘目的:探讨复方丹参注射液联合拉贝洛尔对子痫患者肝功能与胎盘生长因子的影响。方法:选取70例子痫患者,随机分为对照组和观察组各35例。对照组采用拉贝洛尔进行治疗,观察组在对照组的治疗基础上联合复方丹参注射液治疗,联合分析两组肝功能[丙氨酸转氨酶(ALT)、谷草转氨酶(AST)、总蛋白(TP)、白蛋白(ALB)]、血液流变学指标、胎盘生长因子(PLGF)、血清胰岛素样生长因子-1(IGF-1)及临床指标情况。结果:治疗后,观察组患者丙氨酸转氨酶(ALT)、谷草转氨酶(AST)水平显著低于对照组,观察组总蛋白(TP)、白蛋白(ALB)水平显著高于对照组,差异有统计学意义(P<0.05);观察组治疗后高切及低切全血黏度,血浆黏度及红细胞刚性指数评估指标明显低于对照组,差异有统计学意义(P<0.05);观察组治疗后PLGF及IGF-1评估指标水平高于对照组,差异有统计学意义(P<0.05);观察组治疗后生产孕周、新生儿体重指标、胎盘重量及新生儿1 min Apgar评分情况高于对照组,差异有统计学意义(P<0.05)。结论:对子痫患者采用复方丹参注射液联合拉贝洛尔治疗,可有效控制患者的病情,改善患者的肝功能及胎盘生长因子状况,且安全性较高。
文摘Objective: The purpose of this study was to determine if maternal serum concentrations of placenta growth factor(PlGF) and soluble Fms-like tyrosine kinase 1 receptor(s-Flt1) are more abnormal in patients with severe preeclampsia compared with mild preeclampsia. Study design: Serum samples were collected from 32 control patients and 80 patients with mild or severe preeclampsia. PlGF and s-Flt1 concentrations were quantitated by enzyme-linked immunosorbent assay (ELISA). Results are expressed as median(Q1-Q3) unless stated otherwise. After normalization, serum markers were compared using one-way analysis of covariance (ANCOVA). Results: Patients with preeclampsia had decreased levels of PlGF(75.1±14 vs 391±54 pg/mL, P< .0001) and elevated s-Flt1 concentration(1081±108 vs 100.1±26.9 pg/mL, P< .0001) compared with the respective controls(mean±SEM). PlGF concentration was lower in patients with mild preeclampsia compared with severe, respectively(67 pg/mL [39-158] vs 24 pg/mL [4-57], P< .02). s-Flt1 was not different between mild and severe preeclampsia(674 pg/mL [211-1297] vs 1015 pg/mL [731-1948], P=.08). Conclusion: PlGF and s-Flt1 serum levels are abnormal in patients with preeclampsia compared with controls, but only PlGF is more abnormal in severe preeclampsia compared with mild preeclampsia.
文摘Objective: To assess the possible role of human Urotensin-II (hU-II), a vaso active peptide, in the pathophysiology of preeclampsia-eclampsia prospectively. Study design: Sixty subjects, 30 with a diagnosis of preeclampsia-eclampsia (g roup I) and 30 control subjects (group II), who had been admitted between Januar y, 2002 and December, 2002, were taken into the study. Patients in group I had a n increase in blood pressure after 28th week of gestation, without any history o f hypertensive disease and/or preeclampsia or eclampsia. hU-II levels were asse ssed using a radioimmunoassay method. Results: No statistically significant diff erence in terms of age, gestational age, gravidity, abortion and parity was dete cted among groups (P >0.05). Plasma hU-II levels in the preeclampsia-eclampsia and control groups were 10.11 ±5.94 pg/mL and 3.93 ±1.73 pg/mL, respectively. Difference between plasma hU-II levels of the two groups was found to be stati stically significant (P < .00001). Also there was correlation between hU-II lev els and mean arterial pressures in both groups (r = 0.73, P < 0.0001 and r = 0.7 2, P < 0.0001 for groups I and II, respectively). Conclusion: Results of our stu dy strongly suggest an important role for hU-II in the pathophysiology of preec lampsia-eclampsia. Further studies concerning placenta and cord blood samples w ill more clearly elucidate the role of Urotensin-II in the pathogenesis of pree clampsia-eclampsia, and its feto-maternal effects.
